|
|
|
|
|
|
|
||
Articles |
Expression by T Cells
Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02115
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
expression in the development of T helper cell (Th)1–type pathology were examined in two different models of experimental colitis. In each model, abnormal reconstitution of the T cell compartment in immunodeficient mice by adoptive cell transfer leads to a wasting syndrome and inflammation of the colon, induced by IFN- and tumor necrosis factor (TNF)-
–producing T cells. We show here that treatment with anti–IL-12 antibodies in one of the models, or reconstitution with T cells from Stat-4–deficient (Stat-4null) mice in both models resulted in a milder disease in the majority of recipient animals, compared with those that were left untreated or that had been reconstituted with wt cells. Protected mice in each group also harbored lower frequencies of IFN-–producing T cells than did diseased mice, suggesting that effects on wasting and colitis resulted from the attenuation of IFN- expression by T cells. To test whether the development of pathogenic T cells in the two colitis models was directly dependent on T cell–specific IFN- expression, IFN-null donors were used for T cell reconstitution in each system. Surprisingly, large numbers of IFN-null–reconstituted mice developed wasting and colitis, which in many cases was of comparable severity to that seen in animals reconstituted with wt cells. Furthermore, T cells from these animals expressed TNF-, demonstrating that they had retained the ability to produce another proinflammatory cytokine. Taken together, these results demonstrate that in some forms of chronic experimental colitis the development of pathogenic T cells is influenced predominantly, though not exclusively, by IL-12 via the actions of Stat-4 proteins. Furthermore, our data suggest that in the models of colitis studied here the effects of IL-12/Stat-4 or other Th1 promoting pathways are not limited to the induction of IFN- gene expression in T lymphocytes.
Several rodent models of chronic intestinal inflammation share features of immunopathology with human inflammatory bowel disease (IBD),1 which exists in the two distinct forms of Crohn's disease and ulcerative colitis (1–6). In particular, the finding that human and many animal forms of IBD show evidence of aberrant Th1 responses has come under close scrutiny (5, 7–12). Most recently, it has been proposed that mucosal inflammation, such as that found in IBD, emerges from an alteration in the normal balance between the effects of proinflammatory cytokines such as IFN-
Evidence that IL-12 is important in intestinal inflammation has recently been provided in an experimental model of acute granulomatous colitis, induced by administration of trinitrobenzene sulphonic acid (TNBS), which could be prevented by treatment with an anti–IL-12 antibody (21). The absence of IFN-
Although the IL-12/Stat-4 pathway clearly predominates in the development of Th1 type T cells, Stat-4–deficient T cells are nevertheless capable of limited IFN-
In each colitis model, wasting and intestinal pathology has been shown to be generated by the abnormal reconstitution of the T cell compartment in nonallogeneic, immunodeficient mice. In the first system, we have previously shown that disease develops after bone marrow cell (BMC) reconstitution of T cell and NK cell–deficient Tg
In both the BM
Cell and Bone Marrow Purification and Cell Transfer.
For the BM
To reduce the possibility of graft versus host disease (GVHD) in the CD45RBhi model, cell transfers were made, where possible, between mice of the same backgrounds. Stat-4null mice were of the mixed background C57BL/6 x 129/SvEv, making responses against segregated minor antigens from the 129/SvEv donor background a possibility. However, no evidence of GVHD, such as skin inflammation, was observed in any of the animals studied. In the Tg
Antibody Treatment.
Disease Monitoring and Scoring.
Histological Analysis.
Cell Preparations and Cytokine Analysis.
Treatment of BM and regulatory cytokines such as transforming growth factor β (TGF-β; reference 13). The observation that TGF-β–deficient mice develop inflammation of various tissues, including the intestine, provides strong evidence in support for this (14). IL-12, a cytokine produced by activated macrophages and dendritic cells, plays a central role in the generation of Th1-type responses, characterized predominantly by the induction of IFN- production in T cells (15–20). In light of this, elucidation of the mechanisms by which IL-12 might promote mucosal inflammation is of clear importance for understanding the pathogenesis of IBD. expression in protected animals in these experiments was consistent with other data that has shown that IL-12 activity correlates strongly with IFN- expression by T cells (19, 22, 23). Recent studies have extended these observations by demonstrating that induction of IFN- expression in Th1 cells depends largely upon the activity of intracellular signal transducer and activator of transcription 4 (Stat-4) proteins, which mediate signals via the IL-12 receptor (24–28). Although IL-12 activates other members of the Stat protein family (including Stat-3; reference 27), the effects of this cytokine on Th1 cell development have been shown to depend specifically on expression of Stat-4. Consistent with this, T cells from Stat-4null mice are almost completely unable to produce IFN- in response to IL-12 and show reduced Th1 responses equivalent to those in IL-12null mice (28–30). production in response to IL-12–independent stimuli, such as CD3–IL-2 costimulation (28, 29). Additionally, IFN- has been shown to efficiently augment IL-12–mediated differentiation of Th1 cells (31). These data leave open the possibility that pathways other than that provided by IL-12 and Stat-4 contribute to the expression of IFN- and development of Th1-mediated inflammation. Furthermore, such experiments beg the question as to whether induction of IFN- gene expression in T cells does in fact represent the critical step in the development and action of pathogenic Th1 type cells. For example, it is possible that T cells could be induced into a Th1-like state in the absence of autocrine IFN- expression, and induce pathology through expression of other proinflammatory mediators. In this study we sought to examine these questions by testing the extent to which Stat-4 signaling and the resulting IFN- production by T cells contribute to pathology in two distinct Th1 models of colitis. 
26 (C57BL/6 x CBA/J) mice, using (C57BL/6 x CBA/J)F1 donor animals (BM
Tg26) (32–34). In the second system, IBD was originally shown to be induced upon reconstitution of CB.17 Scid mice with CD45RBhi CD4+ T cells from wt Balb/c or CB.17 animals (35–39). In both models, strong evidence exists to suggest that pathology develops through a lack of normal T cell regulation. In the case of the CD45RBhi transfer model, this occurs due to the absence of CD45RBlo CD4+ T cells, which exert their regulatory effects through the expression of IL-10 and TGF-β (38). Similarly, we have provided evidence in the BM Tg26 model that abnormal T cell regulation, resulting from aberrant development of thymus-derived T cells, is causal in the development of pathology in these mice (34). Central to our hypothesis is the observation that the thymi of Tg26 mice lack a normal stromal architecture and thus are unable to support normal ontogeny of wt donor–derived thymocytes supplied by bone marrow inoculation. Consequently, we have suggested that this defect in thymocyte development prevents the establishment of a regulated T cell repertoire in BM Tg26 mice. Tg26 and CD45RBhi transfer models, the notion that T cell dysregulation leads to aberrant Th1 responses is underscored by the presence of very large numbers of activated IFN-– and TNF-–secreting T cells in the peripheral lymphoid tissue and the colon (38, 40). However, despite the similarity of the T cell phenotype in each model, the resulting pathology in each case is clearly distinct. Thus, in the BM Tg26 mice, inflammation is limited to the mucosa of the colon and shares some features of UC, including crypt abscess formation, crypt cell proliferation, and extensive mononuclear cell infiltration. Although these are also characteristic of the CD45RBhi transfer model, colitis in these mice displays additional features resembling some of those observed in Crohn's disease, including transmural inflammation, formation of granulomas, and occasional involvement of the distal small intestine. These distinctions provide a useful means by which to compare mechanisms important in alternative forms of chronic intestinal inflammation. Furthermore, since each system uses adoptive transfer of cells into T–cell deficient host animals, both are amenable to a novel experimental design whereby alternative chimeras can be generated using donors genetically deficient in specific proteins of interest. Using this as one of our approaches, we investigated the requirements for IL-12/Stat-4 signaling and induction of T cell–specific IFN- gene expression in the development of pathology in each form of colitis.
Materials and Methods
Top
Abstract
Materials and Methods
Results
Discussion
References
Mice.
Donor (C57BL/6 x CBA/J)F1, C57BL/6, C57BL/6/ Scid, and C57BL/6/IFN-null mice were purchased from The Jackson Laboratory (Bar Harbor, ME). The Stat-4null mice were a gift from Dr. J.N. Ihle (St. Jude's Children's Hospital, Memphis, TN). 129/SvEv RAG-2null and wt mice were purchased from Taconic Farms (Germantown, NY). The Tg26 recipient mice were generated as previously described by transgenic overexpression of a full-length human CD3 gene (32) and bred on the original C57BL/6 x CBAJ background in the Beth Israel Deaconess Medical Center animal facility. All mice were kept under standard conditions in microisolator cages with autoclaved food, water, and bedding. In RAGnull and Scid reconstitution experiments, recipients were between 4 and 6 wk of age. Tg26 recipient mice were between 5 and 10 wk of age.
The CD45RBhi model was generated as described by Powrie et al. with minor modifications (37). CD4+ T cells obtained from the spleens of donor animals and were enriched by magnetic sorting. For cell purification, the following biotinylated anti–mouse antibodies were used to label non-CD4+ T cells isolated from the spleens of donor mice: B220 (RA3-6B2), Mac-1 (M1/70), Gr-1(RB6-8C5), and CD8 (53-6.7). Magnetically labeled streptavidin beads (Miltenyi Biotec Inc., Sunnyvale, CA) were used to bind the biotinylated antibodies. All antibodies were obtained from PharMingen (San Diego, CA). Negative selection was accomplished using a MACS magnetic cell sorter (Miltenyi Biotec Inc.). The enriched CD4+ cells were then labeled for cell sorting with FITC-conjugated CD45RB (16A) and PE-conjugated CD4 (Becton Dickinson, Mountain View, CA). Subsequently, cells were sorted under sterile conditions by flow cytometry for CD4+ CD45RBhi cells, using criteria similar to that described in previous studies (37). This resulted in a >98% pure population of T cells. Harvested cells were resuspended at 106/400 ml PBS (no FCS) and injected into the tail veins of recipient mice. Tg26 model, bone marrow was prepared as previously described (34). In brief, BMCs were depleted of T cells using two rounds of treatment with anti-Thy1.2 antibody (30-H12) followed by rabbit complement lysis (Cedarlane Labs, Westbury, NY). This procedure resulted in <0.1% CD4+ and CD8+ cells within the inoculum, as determined by flow cytometry. Bone marrow recipients were total body irradiated with a sublethal dose (400 rads) 6–8 h before transplant or were treated with 5-Fluorouracil (75 mg/kg) 48 h before transplantation. 5 x 106–107 cells were resuspended in 400 ml PBS (no FCS) and transferred by tail vein injection. 26 bone marrow transfer model, significant differences were present between donor and recipient mice in some cases. However, preconditioning of bone marrow was effective in depleting the BMCs of T cells (see above). Inflammation of the skin and small bowel were not apparent in the mice included in this study.
The anti–IL-12 antibody (clone C 17.8; reference 16) was a gift from Dr. T. Veldman (Genetics Institute, Cambridge, MA). 260 µg of purified anti–IL-12 antibody (or vehicle control [PBS]) was injected intraperitoneally into mice on a weekly basis starting at the time of BMC transfer.
Mice were weighed twice a week and monitored for appearance and signs of loose stool and diarrhea. In the BM Tg26 model, the level of wasting was determined by percentage of loss of weight from the starting weight, measured at the time of transplant. Weights were subsequently ranked 1 point for every 10% of body weight (or part thereof) lost: 0 = no weight loss; 1 = 1–10% weight loss; 2 = 11–20% weight loss; and 3 = 
21% weight loss. At necropsy animals were assessed for the level of colitis, which they displayed using two parameters: colon thickening and stool consistency, which were subsequently ranked as follows: for colon enlargement, 0 = no colon thickening; 1 = mild thickening; 2 = moderate thickening; 3 = extensive thickening; and for stool consistency, 0 = normal beaded stool; 1 = soft stool; 2 = diarrhea; and an additional point was added if gross blood was noted. The total score given for disease was the combined scores for colon thickening, stool consistency, and weight loss, divided by three.
Colon tissue samples were fixed in 10% buffered formalin and embedded in paraffin. Sections (4 µm) were cut and placed on gelatin-coated microscope slides for staining with hematoxylin and eosin using standard techniques as previously described (34). The severity of colitis was determined based on histological examination of the distal colon, whereby the extent of colonic inflammation was graded on a scale of 0–3 in each of three criteria: cell infiltration, thickening of the bowel wall, and the number of crypt abscesses. Histological grades were assigned in a blinded fashion by the same pathologist (A.K. Bhan).
Mesenteric lymphocytes were harvested and single cell suspensions prepared in PBS with 2% FCS (Intergen, Purchase, NY). Viable cells were counted and determined by trypan blue exclusion. Surface and cytoplasmic staining and FACS® (Becton Dickinson, Indianapolis, IN) analysis were performed as previously described (40). All antibodies were purchased from PharMingen and were conjugated to PE, FITC, or biotin. In the case of biotin-conjugated antibodies, labeling was accomplished by secondary staining with streptavidin-RED670 (GIBCO BRL). Cytoplasmic staining for IFN- (clone XMG1.2) and TNF- (clone MP6-XT22) was done as previously described (40). In brief, freshly isolated cells were stimulated overnight with plate-bound anti-CD3 (clone 145-2C11). Brefeldin A was added for the final 2 h of incubation at a final concentration of 10 mg/ ml. Cells were stained with anti-CD4 (clone RM4-5) and anti– CD3-biotin (145-2C11), washed, and fixed with 2% paraformaldehyde (Sigma Chemical Co., St. Louis, MO). Cells were permeabilized with Saponin (0.2% in PBS) to facilitate cytoplasmic cytokine staining. Cells were analyzed by flow cytometry using a FACscan® flow cytometer in conjunction with FACScan® software (Becton Dickinson) and CellQuest Software (Becton Dickinson).
Results
Top
Abstract
Materials and Methods
Results
Discussion
References
The IL-12/Stat-4 Pathway Predominates in Development of Wasting and Intestinal Pathology in Two Models of Colitis.
To examine the role of IL-12 in the BM Tg26 colitis model, Tg26 mice were transplanted with BMCs from (C57BL/6 x CBA)F1 donors as previously described (34) and given a weekly dose of anti–IL-12 antibody, or vehicle control (PBS). The requirement for Stat-4 expression in T cells was tested by comparing disease in Tg26 mice transplanted with BMCs from Stat-4null mice or wt control animals of the same genetic background (129/SvEv). Using a similar approach in the CD45RBhi model, we used 129/ SvEv RAGnull mice, rather than CB.17/SCID mice, as recipients, allowing us to maintain an equivalent genetic background to the Stat-4null donor animals (see Materials and Methods). RAGnull mice were thus reconstituted with FACS®-sorted splenic CD4+ CD45RBhi T cells from Stat-4null mice (Stat-4null RAGnull). Control RAGnull mice in these experiments were transplanted with wt 129/SvEv CD4+ CD45RBhi T cells (129/wt RAGnull). Tg26 mice with anti–IL-12 antibody resulted in a significant reduction in disease compared with control (untreated) mice. A gross clinical disease activity score, which measures stool consistency, gross colon enlargement, and weight loss, is shown in Fig. 1. The difference in the extent of disease was most apparent between 4 and 5 wk after BMC transfer, where control animals showed signs of severe cachexia, and in many cases diarrhea which was occasionally accompanied by visible blood. By comparison, anti–IL-12–treated animals showed reduced wasting and generally did not develop diarrhea. At necropsy, the colons of treated animals were also visibly less thickened than those of control mice. Similarly, the majority of Tg26 reconstituted with Stat-4null BMCs showed milder disease compared with control animals that had received wt BMC (Fig. 1). 129/wt RAGnull mice developed wasting and colitis 7–10 wk after cell transfer. In contrast, Statnull RAGnull retained a healthy appearance over the same period of time and showed mild colitis at necroscopy, similar to that seen in RAGnull mice that had received sorted CD4+ CD45RBlo T cells (36, 37).
|
Tg26 mice, and the majority of Stat-4null reconstituted mice, was lower than in control animals. Nevertheless, significant histological colitis could be detected in a proportion of Stat-4null recipient animals, even in cases where severe gross colitis (extensive colon thickening and diarrhea) was not apparent. In Stat-4null RAGnull experiments, a large majority of animals showed considerably lower grades of colitis than did control mice. Representative histological sections from colons of CD45RBhi RAGnull and BM Tg26 mice from different groups are shown in Fig. 3, illustrating the principal differences between mild and severe forms of colitis in each model. The limited extent of mucosal inflammation in most of the Stat-4null-recipients and in those subjected to anti–IL-12 antibody treatment was evident from the nominal level of cellular infiltration, crypt cell hyperplasia, and the paucity of crypt cell abscesses formation. However, it was noted, in the colons of some Stat-4null RAGnull mice, that even in the absence of continuous mucosal inflammation there was a moderate frequency of focal inflammatory involvement. In some cases this was accompanied by the appearance of granulomas, a characteristic feature of the CD45RBhi transfer model (Fig. 3 D). Collectively, the use of anti–IL-12 antibodies and Stat-4null mutant mice as donors revealed a predominant role for IL-12 and Stat-4 proteins in the development of both the wasting syndrome and colon inflammation in two distinct models of IBD.
|
|
by Th1 Cells. by T cells, we used cytoplasmic staining of IFN- and FACS® analysis to determine the frequencies of T cells capable of IFN- expression. As shown in Fig. 4, the frequency of IFN-–producing CD4+ T cells in the mesenteric lymph nodes (MLNs) in anti–IL-12–treated F1 Tg26 mice and in Stat-4null Tg26 and Stat-4null RAGnull mice was 60– 80% lower than in control animals. Additionally, numbers of colon lamina propria CD4+ T cells capable of IFN- production were also markedly reduced in protected animals (data not shown). Previous reports have suggested that in the absence of Stat-4 signaling T cells develop a Th2-like phenotype (29). Examination of IL-4 and IL-10 expression by MLN T cells in Stat-4null recipients revealed no detectable expression of either cytokine (data not shown).
|
–deficient T Cells Mediate Disease and Produce TNF-. production and the extent of wasting and colitis. We reasoned that if induction of IFN- gene expression did in fact represent a critical step in the development of pathogenic Th1 cells, then the ablation of this, specifically in T cells, should be sufficient to prevent disease. To test this, we reconstituted the T cell compartment of Tg26 and Scid or RAGnull mice using IFN-–deficient donors (IFN-null mice; reference 41).
In the BM Tg26 model, animals injected with BMCs from IFN-null donors backcrossed to the C57BL/6 background were compared with controls injected with C57BL/ 6/wt BMCs. In the CD45RBhi transfer model, CD45RBhi CD4+ T cells from IFN-null mice were transferred into C57BL/6/Scid or RAGnull mice. Scid and RAGnull mice transplanted with C57BL/6/wt CD4+ CD45RBhi T cells served as controls in these experiments. Fig. 5 shows the cumulative results from these experiments, which compare the mean disease activity scores from each group. In both BM Tg26 and CD45RBhi Scid RAGnull animals little difference was apparent between the overall gross disease in each group of mice (Fig. 5). However, in some cases, weight loss and/or histological colitis were milder in IFN-null–recipient mice (Fig. 6, A and B). A large number of IFN-null Tg26 mice showed a range of histological scores and, in some cases, despite showing clinical evidence of significant colitis, revealed comparatively mild inflammation of the mucosa by histological examination (Fig. 6 B). In CD45RBhi Scid/ RAGnull experiments, most animals showed visible signs of wasting. However, due to their young age at the time of cell transfer, many of these mice increased in body mass due to compensatory growth. The extent of colon involvement observed in the large majority of CD45RBhi Scid/ RAGnull mice was equivalent whether or not animals had received IFN-null or C57BL/6/wt T cells. Representative histological sections from mice that developed colitis in the presence of IFN-null T cells are shown in Fig. 7. In each case the salient features of pathology were similar to those in animals reconstituted with wt T cells.
|
|
|
–reconstituted animals expressed a pattern of cell surface markers consistent with an activation or memory status, including low CD45RB and L-selectin expression and elevated CD69 expression (data not shown). To examine whether, in the absence of IFN- expression, these T cells retained other characteristics consistent with a pathogenic phenotype, their ability to produce TNF- was tested. As shown in Fig. 8, equivalent frequencies of CD4+ T cells from IFN-null and wt recipients in each model expressed TNF-. Taken together, these data demonstrate that without producing IFN- themselves, T cells in each of the IBD models were nevertheless capable of mediating significant levels of wasting and colitis that correlated with the retained capacity of these cells to produce a proinflammatory cytokine.
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Tg26 and the CD45RBhi transfer systems establishes a principal role for this pathway in the development of pathogenic Th1-type T cells in colitis. Furthermore, the similar attenuation of both disease and T cell–specific IFN- expression seen in anti–IL-12–treated BM Tg26 mice and Stat-4null Tg26 mice underscores the link between the actions of IL-12 and Stat-4. In the two colitis models studied here, inhibition of IL-12 and/or Stat-4 signaling affected two divisible aspects of disease, colitis and wasting, implicating involvement of Th1 cells in both components of pathology.
To an extent, our experimental results appear consistent with those obtained in the more acute TNBS-induced model of colitis (21). However, we observed that although disease was for the most part attenuated in the absence of IL-12/Stat-4 signaling, many animals nevertheless revealed evidence of pathology. Furthermore, this correlated with the continued (although strongly reduced) presence of T cells capable of IFN- expression. These data differ from those in the TNBS colitis model, where an almost complete inhibition of both disease and IFN- production were observed after anti–IL-12 treatment. These differences make apparent that the mechanisms of pathology in colitis models studied here and that induced by TNBS are not equivalent, and they suggest that factors other than IL-12 contribute to the development of more chronic forms of intestinal inflammation. In this capacity, the recently described IFN-–inducing factor (IL-18) is a potential candidate, since this cytokine has been shown to have a significant effect on the long-term ability of T cells to produce IFN- (42–44). By inference it is likely that this could significantly affect the development of pathogenic Th1-like T cells.
Notwithstanding the above arguments, the results from our study suggest a degree of independence between the actions of IL-12 and/or other Th1-promoting cytokines and the specific expression of IFN- by T cells. Thus, although the absence of IFN- expression by T cells altered the severity of colitis in many cases, the overall effects on disease were less pronounced than might have been anticipated. On first assessment this is surprising, principally for three reasons. First, the dependence of IFN- expression on IL-12 signaling suggests that the effects of IL-12 (via Stat-4) result from its ability to induce IFN- transcription in T cells (22). Second, IFN- has been shown to be required for efficient IL-12 priming of Th1 cells, presumably through autocrine expression (45–47). Principally, this appears to be achieved through the upregulation of the IL-12 receptor (48–49). Third, a general consensus exists that the well-documented proinflammatory effects of IFN- are central to pathology in IBD (4, 7, 13). The validity of this last assumption in experimental colitis has been strengthened by a previous study by Powrie et al., who demonstrated that anti–IFN- treatment was effective in reducing disease in the CD4+ CD45RBhi transfer model (38). It is possible that in this latter case anti–IFN- antibody treatment might block all available IFN-. By contrast, in our experiments non-T cells, resident in the host animals, might remain a sufficient source of IFN- to promote effects on both T cells and macrophages. However, the development of colitis in the absence of IFN- expression is not unprecedented, since IL-2null mice, which succumb to a Th1-type colitis similar to that seen in BM Tg26 mice, also develop disease after import of the IFN-null mutation (Zand, M., C. Stevens, and T. Strom, personal communication). In addition, a recent study by Berg et al. revealed that antibody neutralization of IFN- in IL-10null mice was sufficient to prevent disease only when administered to animals at 3 wk of age and not in animals aged 3 mo or older (50). Thus, although IFN- was required to establish colitis in IL-10null mice, other inflammatory mediators were clearly sufficient to mediate disease once a pathogenic T cell phenotype had been established.
In two autoimmune models classically associated with Th1-type T cell responses, it has been observed that Th2 cells are also capable of mediating disease (51, 52). These studies support the contention that, in some cases, immunopathology normally associated with Th1-type responses can also be attributable to cells that have undergone immune deviation, leading to the expression of Th2-associated cytokines. However, in our studies we were unable to detect any IL-4 or IL-10 expression in the absence of either Stat-4null or IFN- expression by T cells. Although these findings do not unequivocally demonstrate lack of immune deviation, they do argue that this is not predominant in the colitis models studied here.
Collectively, the results offered here lend credence to the argument that Th1-type cells develop pathogenicity via a complex range of mechanisms, not all of which fall under the influence of IL-12 or their ability to produce IFN-. Ultimately, this is most likely achieved by the concerted expression of a range of cytokines and cytotoxic molecules which could act directly or indirectly to promote inflammation. TNF-, which is produced by T cells as well as macrophages, is a cytokine that encompasses these characteristics and is known to induce potent inflammatory effects. Consistent with this, we have shown that in colitic mice T cells expressed TNF- at a similar frequency whether IFN- was expressed by the same cells or not. Furthermore, we have found that anti–TNF- antibody treatment is highly effective in reducing disease in the BM Tg26 model.2 Similarly, Powrie et al. demonstrated an effect of anti–TNF- treatment in the CD45RBhi Scid model (38). These data are consolidated by the finding that anti–TNF- antibody therapy has been shown to be efficacious in treating Crohn's disease (53).
In summary, our study offers insights into the requirements for both the development and pathogenic activity of Th1-type cells in two distinct models of inflammatory colitis. The observations that IL-12 is upregulated in human IBD (7) and that interruption of the TNF- pathway inhibits Crohn's disease correlate well with our observations in the two models studied here (38).2 Further dissection of the pathways which lead to aberrant Th1 pathology in animal models of IBD will undoubtedly provide a useful source of information for future therapy in IBD.
|
Acknowledgments |
|---|
This work was supported by grants from the Crohn's and Colitis Foundation of America (C. Terhorst) and from the National Institutes of Health (P30 DK-43551 and RO1 DK-47677 to A.K. Bhan). Samir A. Shah is a Howard Hughes Medical Institute Physician Postdoctoral Fellow. Stephen J. Simpson was supported by a Research Fellowship Award from the Crohn's and Colitis Foundation of America.
Submitted: 22 September 1997
Revised: 22 December 1997
Tg26, (C57BL/6 x CBA/J)F1; BMC; bone marrow cells; IBD; inflammatory bowel disease; Stat, signal transducer and activator of transcription; TGF, transforming growth factor. Stephen J. Simpson's present address is Education and Research Centre, St. Vincent's Hospital, Dublin 4, Ireland.
Simpson and Shah contributed equally to this work.
2 Mackay, F., J. Browning, P. Lawton, S. Shah, M. Comiskey, A.K. Bhan, E. Mizoguchi, C. Terhorst, and S. Simpson, manuscript submitted for publication.
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
1 Podolsky DK. Inflammatory bowel disease, N Engl J Med, 1991, 325, 928–937.[Medline]
2 MacDonald TT. Gastrointestinal inflammation. Inflammatory bowel disease in knockout mice, Curr Biol, 1994, 3, 261–263.[Medline]
3 Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease, Gastroenterol Clin North Am, 1995, 24, 475–507.[Medline]
4 Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations, Gastroenterology, 1994, 106, 533–539.[Medline]
5 Simpson, S.J., G.A. Hollander, E. Mizoguchi, A.K. Bhan, B. Wang, and C. Terhorst. 1996. Defects in T-cell regulation: lessons for inflammatory bowel disease. In Essentials of Mucosal Immunology. M.F. Kagnoff and H. Kiyono, editors. Academic Press Inc., San Diego, CA. 291–304.
6 Stenson, W.F. 1994. Animal models of inflammatory bowel disease. In Inflammatory Bowel Disease: From Bench to Bedside. S.R. Targan, editor. Williams and Wilkins, Baltimore, MD. 180–192.
7 Parronchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A, Giannarini L, Maggi E, Pupilli C, Tonelli F & Romagnani S. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease, Am J Pathol, 1997, 150, 823–832.[Abstract]
8 Fiocchi C, Binion DG & Katz JA. Cytokine production in the human gastrointestinal tract during inflammation, Current Opinion in Gastroenterology, 1994, 2, 639–644.
9 Murata Y, Ishiguro Y, Itoh J, Munakata A & Yoshida Y. The role of proinflammatory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis, J Gastroenterol, 1995, 30(Suppl.), 56–60.[Medline]
10 Niessner M & Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR), Clin Exp Immunol, 1995, 101, 428–435.[Medline]
11 Radford-Smith G & Jewell DP. Cytokines and inflammatory bowel disease, Bailliere's Clin Gastroenterol, 1996, 10, 151–164.[Medline]
12 Powrie F. T cells in inflammatory bowel disease: protective and pathogenic roles, Immunity, 1995b, 3, 171–174.[Medline]
13 Strober W, Kelsall B, Marth T, Ludviksson B, Erhardt R & Neurath M. Reciprocal IFN- and TGF-β responses regulate the occurrence of mucosa inflammation, Immunol Today, 1997, 18, 61–64.[Medline]
14 Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D et al.. Targeted disruption of the mouse transforming growth factor–beta 1 gene results in multifocal inflammatory disease, Nature, 1992, 359, 693–699.[Medline]
15 Trinchieri G. Interleukin-12: a pro-inflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity, Annu Rev Immunol, 1995, 13, 251–276.[Medline]
16 Ozmen L, Pericin M, Hakimi J, Chizzonite RA, Wysocka M, Trinchieri G, Gately M & Garotta G. Interleukin 12, interferon , and tumor necrosis factor are the key cytokines of the generalized Shwartzman reaction, J Exp Med, 1994, 180, 907–915.
17 Gerosa F, Paganin C, Peritt D, Paiola F, Scupoli MT, Aste-Amezaga M, Frank I & Trinchieri G. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon and interleukin 10, J Exp Med, 1996, 183, 2559–2569.
18 Heufler C, Koch F, Stanzl U, Topar G, Wysocka M, Trinchieri G, Enk A, Steinman RM, Romani N & Schuler G. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon- production by T helper 1 cells, Eur J Immunol, 1996, 26, 659–668.[Medline]
19 Wysocka M, Kubin M, Vieira LQ, Ozmen L, Garotta G, Scott P & Trinchieri G. Interleukin-12 is required for interferon-gamma production and lethality in lipopolysaccharide-induced shock in mice, Eur J Immunol, 1995, 25, 672–676.[Medline]
20 Gracie JA & Bradley JA. Interleukin-12 induces interferon-–dependent switching of IgG alloantibody subclass, Eur J Immunol, 1996, 26, 1217–1221.[Medline]
21 Neurath MF, Fuss I, Kelsall BL, Stuber E & Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice, J Exp Med, 1995, 182, 1281–1290.
22 Ryffel B. Interleukin-12: role of interferon- in IL-12 adverse effects, Clin Immunol Immunopathol, 1997, 83, 18–20.[Medline]
23 Schmitt E, Hoehn P, Huels C, Goedert S, Palm N, Rude E & Germann T. T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon- and is inhibited by transforming growth factor–β, Eur J Immunol, 1994, 24, 793–798.[Medline]
24 Cho SS, Bacon CM, Sudarshan C, Rees RC, Finbloom D, Pine R & O'Shea JJ. Activation of STAT4 by IL-12 and IFN-: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation, J Immunol, 1996, 157, 4781–4789.[Abstract]
25 Bacon CM, Petricoin EFR, Ortaldo JR, Rees RC, Larner AC, Johnston JA & O'Shea JJ. Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes, Proc Natl Acad Sci USA, 1995, 92, 7307–7311.
26 Ihle JN. STATs: signal transducers and activators of transcription, Cell, 1996, 84, 331–334.[Medline]
27 Jacobson NG, Szabo SJ, Weber-Nordt RM, Zhong Z, Schreiber RD, Darnell JE Jr & Murphy KM. Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4, J Exp Med, 1995, 181, 1755–1762.
28 Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, Sangster MY, Vignali DA, Doherty PC, Grosveld GC & Ihle JN. Requirement for Stat-4 in interleukin-12–mediated responses of natural killer and T cells, Nature, 1996, 382, 171–174.[Medline]
29 Kaplan MH, Sun YL, Hoey T & Grusby MJ. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice, Nature, 1996, 382, 174–177.[Medline]
30 Magram J, Connaughton SE, Warrier RR, Carvajal DM, Wu CY, Ferrante J, Stewart C, Sarmiento U, Faherty DA & Gately MK. IL-12–deficient mice are defective in IFN production and type 1 cytokine responses, Immunity, 1996, 4, 471–481.[Medline]
31 Wenner CA, Guler ML, Macatonia SE, O'Garra A & Murphy KM. Roles of IFN- and IFN- in IL-12– induced T helper cell–1 development, J Immunol, 1996, 156, 1442–1447.[Abstract]
32 Wang B, Biron C, She J, Higgins K, Sunshine MJ, Lacy E, Lonberg N & Terhorst C. A block in both early T lymphocyte and natural killer cell development in transgenic mice with high-copy numbers of the human CD3 gene, Proc Natl Acad Sci USA, 1994, 91, 9402–9406.
33 Hollander GA, Wang B, Nichogiannopoulou A, Platenberg PP, Van Ewijk W, Burakoff SJ, Gutierrez-Ramos JC & Terhorst C. Developmental control point in induction of thymic cortex regulated by a subpopulation of prothymocytes, Nature, 1995, 373, 350–353.[Medline]
34 Hollander GA, Simpson SJ, Mizoguchi E, Nichogiannopoulou A, She J, Gutierrez-Ramos JC, Bhan AK, Burakoff SJ, Wang B & Terhorst C. Severe colitis in mice with aberrant thymic selection, Immunity, 1995, 3, 27–38.[Medline]
35 Powrie F, Leach MW, Mauze S, Caddle LB & Coffman RL. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in CB-17 Scidmice, Int Immunol, 1993, 5, 1461–1471.
36 Morrissey PJ, Charrier K, Braddy S, Liggitt D & Watson JD. CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+T cells, J Exp Med, 1993, 178, 237–244.
37 Powrie F, Leach MW & Mauze S. Inhibition of TH1 responses prevents IBD in SCID mice reconstituted with CD45RBhighCD4+ T cells, Immunity, 1994, 1, 553–562.[Medline]
38 Powrie F, Carlino J, Leach MW, Mauze S & Coffman RL. A critical role for transforming growth factor-β but not interleukin 4 in the suppression of T helper type 1–mediated colitis by CD45RBlow CD4+T cells, J Exp Med, 1996, 183, 2669–2674.
39 Powrie F, Correa-Oliveira R, Mauze S & Coffman RL. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+T cells are important for the balance between protective and pathogenic cell–mediated immunity, J Exp Med, 1994, 179, 589–600.
40 Simpson SJ, Hollander GA, Mizoguchi E, Allen D, Wang BP & Terhorst C. Expression of pro-inflammatory cytokines by TCRβ+ and TCR
+T cells in an experimental model of colitis, Eur J Immunol, 1997, 27, 17–25.[Medline]
41 Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A & Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon- genes, Science, 1993, 259, 1739–1742.
42 Kohno K, Kataoka J, Ohtsuki T, Suemoto Y, Okamoto I, Usui M, Ikeda M & Kurimoto M. IFN-–inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12, J Immunol, 1997, 158, 1541–1550.[Abstract]
43 Micallef MJ, Ohtsuki T, Kohno K, Tanabe F, Ushio S, Namba M, Tanimoto T, Torigoe K, Fujii M, Ikeda M et al.. Interferon-–inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon- production, Eur J Immunol, 1996, 26, 1647–1651.[Medline]
44 Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K et al.. Cloning of a new cytokine that induces IFN- production by T cells, Nature, 1995, 378, 88–91.[Medline]
45 Gollob JA, Kawasaki H & Ritz J. Interferon- and interleukin-4 regulate T cell interleukin-12 responsiveness through the differential modulation of high-affinity interleukin-12 receptor expression, Eur J Immunol, 1997, 27, 647–652.[Medline]
46 Bradley LM, Dalton DK & Croft M. A direct role for IFN- in regulation of Th1 cell development, J Immunol, 1996, 157, 1350–1358.[Abstract]
47 Nakamura T, Lee RK, Nam SY, Podack ER, Bottomly K & Flavell RA. Roles of IL-4 and IFN- in stabilizing the T helper cell type 1 and 2 phenotype, J Immunol, 1997, 158, 2648–2653.[Abstract]
48 Szabo SJ, Dighe AS, Gubler U & Murphy KM. Regulation of the interleukin (IL)-12R β2 subunit expression in developing T helper 1 (Th1) and Th2 cells, J Exp Med, 1997, 185, 817–824.[Medline]
49 Rogge L, Barberis-Maino L, Biffi M, Passini N, Presky DH, Gubler U & Sinigaglia F. Selective expression of an interleukin 12 receptor component by human T helper 1 cells, J Exp Med, 1997, 185, 825–831.[Medline]
50 Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G, Thompson-Snipes L, Leach MW & Rennick D. Enterocolitis and colon cancer in interleukin-10–deficient mice are associated with aberrant cytokine production and CD4+Th-1–like responses, J Clin Invest, 1996, 98, 1010–1020.[Medline]
51 Lafaille JJ, van de Keere F, Hsu AL, Baron JL, Haas W, Raine CS & Tonegawa S. Myelin basic protein– specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from disease, J Exp Med, 1997, 186, 307–312.
52 Pakela S, Kurrer MO & Katz JD. T helper cells (Th2) T cells induce acute pancreatitis and diabetes in immune-compromised nonobese diabetic (NOD) mice, J Exp Med, 1997, 186, 299–306.
53 van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN & Woody J. Treatment of Crohn's disease with anti–tumor necrosis factor chimeric monoclonal antibody (cA2), Gastroenterology, 1995, 109, 129–135.[Medline]
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|
